source
- Vaderis gets $152M to run Phase 3 of rare bleeding disorder treatmentVaderis Therapeutics’ bet that a type of treatment developed for cancers could work for a rare blood disorder is paying off. The 13-person Swiss startup raised $152 million in a Series B to run a ...Endpoints · 39m ago↗ source
- Vaderis hauls in $152M to test an AKT-targeting drugThe startup is one of at least a few young companies zeroing in on the rare bleeding disorder, hereditary hemorrhagic telangiectasia, with a more precise AKT blocker.BioPharma Dive · 39m ago↗ source
- Scribe Therapeutics launches first gene‑editing IPO in over two years, targeting high‑cholesterol geneScribe Therapeutics, a gene‑editing biotech based in California, announced its initial public offering, the first for a CRISPR‑focused company in more than two years. The company, founded by resea…